MedWellAI reserves Series B preferred shares for planned Apollo Biowellness acquisition

MEDWELLAI INC, 0.00%

MEDWELLAI INC,

MWAI

0.36

0.00%

  • MedWellAI reviewing final due diligence to acquire Apollo Biowellness and subsidiaries including Evolutionary Biologics.
  • Preferred Series B stock class reserved for share exchange tied to transaction and assumption of certain Apollo liabilities.
  • Negotiations continuing with secured creditors and debtholders that must be resolved before closing.
  • Jim Morrison set to return as CEO, president, and board chair at Apollo as work continues to complete transaction alongside current CEO James W. Zimbler.
  • Apollo expected to become Evo Bio subsidiary within MedWellAI once take-over closes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedWellAI Inc. published the original content used to generate this news brief on April 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.